SCHEDULE: Caligan Partners Discloses Stake in Sensei Biotherapeutics

Caligan Partners LP and David Johnson have reported a beneficial ownership stake of 9.40% in Sensei Biotherapeutics, Inc., as of March 31, 2026.

Summary

• Caligan Partners LP and David Johnson have filed a Schedule 13G, indicating their beneficial ownership of Sensei Biotherapeutics, Inc. common stock.
• The filing reports a total of 126,002 shares of common stock, representing 9.40% of the class.
• In addition to common stock, the reporting persons hold Series B Non-Voting Convertible Preferred Stock which, when convertible, may be converted into 361,010 shares of common stock.
• The filing is dated May 15, 2026, with the event date requiring the filing being March 31, 2026.
• The outstanding shares of common stock as of March 23, 2026, were reported as 1,340,281.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports ownership stakes and does not contain operational or financial performance updates.

Positives

• Caligan Partners LP and David Johnson have acquired a significant stake (9.40%) in Sensei Biotherapeutics, Inc., suggesting confidence in the company's future prospects.
• The potential conversion of Series B Non-Voting Convertible Preferred Stock could increase their stake substantially, indicating a long-term investment perspective.

Risks

• The Series B Non-Voting Convertible Preferred Stock is only convertible under specific terms and conditions outlined in its Certificate of Designation, which may present limitations or future hurdles.
• The filing does not provide details on the specific reasons for acquiring this stake, leaving potential strategic intentions open to interpretation.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. The future outlook for Sensei Biotherapeutics, Inc. is not directly addressed in this Schedule 13G filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes by institutional investors. The acquisition of a 9.40% stake by Caligan Partners LP in Sensei Biotherapeutics, Inc. suggests a significant level of interest, potentially positioning Caligan as a key stakeholder in the biotechnology sector.

Stakeholder Impact

• Shareholders: The increased stake by Caligan Partners LP may influence market perception and potentially impact share price dynamics. Other shareholders may look to Caligan's investment as an indicator of value.
• Management: The significant ownership by Caligan Partners LP could lead to increased engagement or influence on corporate strategy and governance decisions.
• Creditors: While not directly impacted by this filing, a significant shift in ownership could indirectly affect perceptions of financial stability and future strategic direction.

Next Steps

• Caligan Partners LP and David Johnson will continue to hold and potentially manage their beneficial ownership in Sensei Biotherapeutics, Inc.
• Future amendments to this Schedule 13G will be filed by the reporting persons as required.

Key Dates

Keywords

Sensei Biotherapeutics, Caligan Partners LP, David Johnson, Schedule 13G, Beneficial Ownership, SEC Filing, Investment, Preferred Stock, Convertible Stock